Thalys(SH:603716) Shang Hai Zheng Quan Bao·2025-06-04 21:15Core Viewpoint - The company has decided to terminate a fundraising project and permanently supplement the remaining funds into working capital due to changes in market conditions and project feasibility [4][12][20]. Group 1: Board Meeting Details - The fifth board meeting was held on June 4, 2025, with all eight directors present, and all resolutions were passed unanimously [3][6]. - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legality and validity of the resolutions [3]. Group 2: Fundraising Project Termination - The project being terminated is the "Expansion of Medical Testing Integrated Marketing and Service Business Scale Project," with remaining uninvested funds amounting to 172.54 million yuan [12][17]. - The decision to terminate the project was influenced by significant changes in the IVD industry policies and market conditions, which have adversely affected the project's feasibility and profitability [18][20]. - The company has used 437.20 million yuan of the total 625.96 million yuan raised from the 2018 non-public offering as of May 31, 2025 [14]. Group 3: Future Plans for Remaining Funds - The remaining funds of 172.54 million yuan will be permanently supplemented into working capital to enhance the efficiency of fund utilization [19][20]. - This decision aligns with the company's long-term operational development strategy and aims to optimize resource allocation [20]. Group 4: Upcoming Shareholder Meeting - The company plans to hold the third extraordinary general meeting of shareholders on June 20, 2025, to discuss the termination of the fundraising project and the use of remaining funds [8][26]. - The meeting will be conducted both in-person and via an online voting system, ensuring broad participation from shareholders [27][30].